136 related articles for article (PubMed ID: 26431331)
1. 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
Ali R; Apte S; Vilalta M; Subbarayan M; Miao Z; Chin FT; Graves EE
PLoS One; 2015; 10(10):e0139425. PubMed ID: 26431331
[TBL] [Abstract][Full Text] [Related]
2. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
5. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
[TBL] [Abstract][Full Text] [Related]
6.
Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
[TBL] [Abstract][Full Text] [Related]
7. Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer.
Narva SI; Seppänen MP; Raiko JRH; Forsback SJ; Orte KJ; Virtanen JM; Hynninen J; Hietanen S
Clin Nucl Med; 2021 Dec; 46(12):952-957. PubMed ID: 34619699
[TBL] [Abstract][Full Text] [Related]
8. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
[TBL] [Abstract][Full Text] [Related]
9. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
Lee J; Siemann DW; Koch CJ; Lord EM
Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
[TBL] [Abstract][Full Text] [Related]
10. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
[TBL] [Abstract][Full Text] [Related]
11. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).
Chitneni SK; Bida GT; Dewhirst MW; Zalutsky MR
Nucl Med Biol; 2012 Oct; 39(7):1012-8. PubMed ID: 22727821
[TBL] [Abstract][Full Text] [Related]
12. Repeatability of tumour hypoxia imaging using [
Silvoniemi A; Suilamo S; Laitinen T; Forsback S; Löyttyniemi E; Vaittinen S; Saunavaara V; Solin O; Grönroos TJ; Minn H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):161-169. PubMed ID: 29075831
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia in human intraperitoneal and extremity sarcomas.
Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
[TBL] [Abstract][Full Text] [Related]
14. Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.
Lin LL; Silvoniemi A; Stubbs JB; Rengan R; Suilamo S; Solin O; Divgi C; Eskola O; Sorger JM; Stabin MG; Kachur A; Hahn SM; Grönroos TJ; Forsback S; Evans SM; Koch CJ; Minn H
Cancer Biother Radiopharm; 2012 Sep; 27(7):412-9. PubMed ID: 22897720
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice.
Murayama C; Harada N; Kakiuchi T; Fukumoto D; Kamijo A; Kawaguchi AT; Tsukada H
J Nucl Med; 2009 Feb; 50(2):290-5. PubMed ID: 19164228
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status.
Evans SM; Jenkins WT; Shapiro M; Koch CJ
Adv Exp Med Biol; 1997; 411():215-25. PubMed ID: 9269430
[TBL] [Abstract][Full Text] [Related]
17. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
[TBL] [Abstract][Full Text] [Related]
20. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.
Eskola O; Grönroos TJ; Forsback S; Tuomela J; Komar G; Bergman J; Härkönen P; Haaparanta M; Minn H; Solin O
Mol Imaging Biol; 2012 Apr; 14(2):205-12. PubMed ID: 21448777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
